Full Press Release Details
REGENERON COMPLETES ENROLLMENT FOR IL-1 TRAP PHASE 3 TRIAL IN AUTOINFLAMMATORY DISEASE Efficacy Phase of Trial on Target for Completion in 2006.
REGN
REGENERON COMPLETES ENROLLMENT FOR IL-1 TRAP PHASE 3 TRIAL IN AUTOINFLAMMATORY DISEASE Efficacy Phase of Trial on Target for Completion in 2006
Key Takeaway: REGENERON COMPLETES ENROLLMENT FOR IL-1 TRAP PHASE 3 TRIAL IN AUTOINFLAMMATORY DISEASE Efficacy Phase of Trial on Target for Completion in 2006
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
2.7%
average across 15 past catalysts
Lead asset
REGN7508
Phase 3 · Venous Thromboembolism